Studies in both human and experimental models demonstrate that myelin repair occurs in the central nervous system and is a normal physiologic response to myelin injury. However, remyelination in MS is often incomplete and limited. The outcome of an actively demyelinating lesion depends on the balance between factors promoting myelin destruction and myelin repair. Experimental models of CNS demyelination provide an opportunity to investigate the morphologic, cellular and molecular mechanisms involved in remyelination. This review focuses on experiments using the Theiler's virus model of demylination which indicate that manipulation of the immune response has the potential to promote endogenous CNS remyelination and functional recovery in MS.
Marburg O. (1906) Die sogenannte 'akute Multiple Sklerose'. Jahrb Psychiatrie27: 211- 312.
2.
Perier O., Greqoire A. (1965) Electron microscopic features of multiple sclerosis lesions. Brain88: 937-952.
3.
Feigin I., Popoff N. (1966) Regeneration of myelin in multiple sclerosis. Neurology16: 364-372.
4.
Suzuki K., Andrews JM, Waltz JM, Terry RD (1969) Ultrastructural studies in multiple sclerosis. Lab Invest20: 444 - 454.
5.
Itoyama Y., Webster H de F,Richardson EP Jr, Trapp BD . (1983) Schwann cell remyelination of demyelinated axons in spinal multiple sclerosis lesions. Ann Neurol14: 339-346.
6.
Prineas JW, Connell F. (1979) Remyelination in multiple sclerosis. Ann Neurol5: 22 - 31.
7.
Prineas JW et al. (1993b) Multiple sclerosis: remyelination of nascent lesions. Ann Neurol33: 137 - 151.
8.
Rodriguez M. , Scheithauer BW, Forbes G., Kelley PJ (1993) Oligodendrocyte injury is an early event in lesions of multiple sclerosis . Mayo Clin Proc68: 627- 636.
9.
Rodriguez M. , Scheithauer BW (1994) Ultrastructure of multiple sclerosis. Ultrastruct Pathol18: 3 - 13.
10.
Lassmann H. (1983) Comparative neuropathology of chronic experimental allergic encephalomyelitis and multiple sclerosis . Schriftner Neurol25: 1 - 135.
11.
Prineas JW (1985) The neuropathology of multiple sclerosis. In: JC Koetsier (ed) Handbook of Clinical Neurology. Vol 47: Demyelinating diseases. Elsevier Science Publ. pp 337-395.
12.
Bruck W. et al. (1994) Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol35: 65 - 73.
13.
Ozawa K. et al. (1994) Patterns of oligodendroglia pathology in multiple sclerosis. Brain117: 1311-1322.
14.
Blakemore WF (1973) Demyelination in the superior cerebellar peduncle in the mouse induced by cuprizone. J Neurol Sci20: 63 - 72.
15.
Yajima K., Suzuki K. (1979) Demyelination and remyelination in the rat central nervous system following ethidium bromide injection. Lab Invest41: 385-392.
16.
Hall SM (1972) The effects of injections of lysophosphatidyl choline into white matter of the adult mouse spinal cord. J Cell Sci13: 257 - 277.
17.
Ludwin SK (1988) Remyelination in the central nervous system and the peripheral nervous system. Adv Neurol47: 215-254.
18.
Ludwin SK (1980) Chronic demyelination inhibits remyelination in the central nervous system: an analysis of contributing factors. Lab Invest43: 382-387.
19.
Gilson J., Blakemore WF (1993) Failure of remyelination in areas of demyelination produced in the spinal cord of old rats. Neuropathol Appl Neurobiol19: 173 - 181.
20.
Zamvil SS, Steinman LS (1990) The T lymphocytre in experimental allergic encephalomyelitis . Ann Rev Immunol8: 579 - 621.
21.
Raine CS, Traugott U. (1985) Remyelination in chronic relapsing experimental allergic encephalomyelitis and multiple sclerosis. In: Adachi M, Hirano A, Aronson SM (eds). The pathology of the myelinated axon. Igaku-Shoin: New York, pp 229-275.
22.
Traugott U. , Stone SH, Raine CS (1982) Chronic relapsing experimental autoimmune encephalomyelitis: treatment with combinations of myelin components promotes clinical and structural improvement. J Neurol Sci56: 65 - 73.
23.
Raine CS, Traugott U. (1983) Chronic relapsing experimental autoimmune encephalomyelitis: ultrastructure of the central nervous system of animals treated with combination of myelin components. Lab Invest48: 275 - 284.
24.
Lang W., Rodriguez M., Lennon VA, Lampert PW (1984) Demyelination and remyelination in murine viral encephalomyelitis. Ann NY Acad Sci436: 98 - 102.
25.
Rodriguez M. , Oleszak E., Leibowitz J. (1987) Theiler's murine encephalomyelitis: a model of demyelination and persistence of virus. CRC Crit Rev Immunol7: 325- 365.
26.
Rodriguez M. , Lennon VA, Benveniste EN, Merrill JE (1987) Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. J Neuropathol Exp Neurol46: 84-95.
27.
Rodriguez M. , Lennon VA (1990) Immunoglobulins promote remyelination in the central nervous system. Ann Neurol27: 12 -17.
28.
Miller DJ, Sanborn KS, Katzmann JA, Rodriguez M. (1994) Monoclonal autoantibodies promote central nervous system repair in an animal model of multiple sclerosis. J Neurosci14: 6230-6238.
29.
Miller DJ, Rodriguez M. (1995) A monoclonal autoantibody that promotes central nervous system remyelination in a model of multiple sclerosis is a natural autoantibody encoded by germline immunoglobulin genes. J Immunol154: 2460 - 2469.
30.
Asakura K., Pogulis R., Pease LR, Rodriguez M. (1996b) A monoclonal autoantibody which promotes central nervous system remyelination is highly polyreactive to multiple known and novel antigens. J Neuroimmunol65: 11 -19.
31.
Asahura K. et al. (1996a) Monoclonal autoantibody SCH94.03 which promotes central nervous system remyelination recognizes an antigen on the surface of oligodendrocytes. J Neurosci Res43: 273 - 281.
32.
Raine CS, Scheinberg LC, Waltz JM (1981) Multiple sclerosis: oligodendrocyte survival and proliferation in an active established lesion. Lab Invest45: 534 - 546.
33.
Lehrer GM et al. (1979) Stimulation of myelin lipid synthesis in vitro by white matter antiserum in the absence of complement. Brain Res172: 557 - 560.
34.
Bansal R., Gard AL, Pfeiffer SE (1988) Stimulation of oligodendrocyte differentiation in culture by growth in the presence of a monoclonal antibody to sulfated glycolipid. J Neurosci Res21: 260 - 267.
35.
Benjamins JA , Dyer CA (1990) Glycolipids and transmembrane signaling in oligodenroglia. Ann NY Acad Sci605: 90 -100.
36.
Rodriguez M. , Lindsley MD (1992) Immunosuppression promotes CNS remyelination in chronic virus-induced demyelianting disease . Neurology42: 348-367.
37.
Miller DJ et al. (1996a) A monoclonal natural autoantibody that promotes remyelination suppresses central nervous system inflammation and increases virus expression after Theiler's virus-induced demyelination. Int Immunol8: 131-141.
38.
Miller DJ et al. (1995) Spontaneous CNS remyelination in beta-2-microglobulin-deficient mice following virus-induced demyelination. J Neurosci15: 8345 -8352.
39.
vanEngelen BG et al. (1994) Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis. J Neurol Neurosurg Psych57: 65 - 68.
40.
Imbach P., Barundun S., d'Apuzzo V. (1981) High-dose intraveneous immunoglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet1: 1228-1231.
41.
Newburger JW , Takahashi M., Burns JC (1986) The treatment of Kawasaki's syndrome with gammaglobulin. N Engl J Med315: 341 - 347.
42.
Kleywig RP, Van der Meche Fga, Meulstee J. (1988) Treatment of Guillan-Barre syndrome with high dose gamma globulin. Neurology38: 1639-1641.
43.
Cornblath DR , Chaudhry V., Griffin JW (1991) Treatment of chronic inflammatory demyelinating polyneuropathy with intraveneous immunoglobulin. Ann Neurol30: 104 -106.
44.
Miller HG et al. (1963) Multiple sclerosis: therapeutic trials of chloroquine, soluble aspirin, and gammaglobulin. Br Med J1: 1436-1439.
45.
Schuller E. , Govaerts A. (1983) First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur Neurol22: 205 - 212.
46.
Cook SD et al. (1992) Intraveneous gamma globulin in progressive multiple sclerosis. Acta Neurol Scand86: 171 - 175.
47.
Yan J., Richert JR, Sirdofsky MD (1990) High-dose intravenous immunoglobulin for multiple sclerosis. Lancet2: 692.
48.
Achiron A., Pras E., Gilad R. (1992) Open controlled therapeutic trial of intravenous immunoglobulins in relapsing-remitting multiple sclerosis. Arch Neurol49: 1233 -1236.
49.
Fazekas F., Deisenhammer F., Strasser-Fuchs S. et al. (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis . Lancet349: 589-593.
50.
Frohman LP, Cook SD, Bielroy L. (1991) Dysgammaglobulinemia in steroid-dependent optic neuritis: response to gammaglobulin treatment. J Clin Neuro Ophthalmol11(4): 241- 245.
51.
vanEngelen Bgm et al. (1992) Improved vision after intraveneous immunoglobulin in stable demyelinating optic neuritis. Ann Neurol32: 835-836.
52.
Noseworthy JH, O'Brien PC, vanEngelen BG, Rodriguez M. (1994) Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial . J Neurol Neurosurg Psychiat57(Suppl): 11 - 14.
53.
Kurtzke JF (1973). Studies on the natural history of multiple sclerosis. Correlates of clinical change in an early bout. Acta Neurol Scand49: 379 - 395.
54.
Sandberg-Wolheim M. et al. (1990) A longterm prospective study of optic neuritis: evaluation of risk factors. Ann Neurol27: 386 - 393.
55.
Riikonen R. , Donner M., Erkkila H. (1988) Optic neuritis in children and its relationship to multiple sclerosis: a clinical study of 21 children . Dev Med Child Neurol30: 349-359.
56.
Beck RW et al. (1992) A randomized controlled trial of corticosteroids in the treatment of optic neuritis. NEngl J Med326: 581- 588.
